Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, play a crucial role in glucose metabolism by enhancing the glucose-dependent secretion of insulin from pancreatic beta cells and inhibiting glucagon release from alpha cells, thus lowering blood glucose levels postprandially (Holst, 2007)
Na razie jest jeszcze na to za wczenie
Phase 2 Clinical Trial Data The landmark Phase 2 trial of retatrutide in obesity was a 48-week, randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2023
But experts stress that they are not magic pills
Last quarter, the company submitted its drug orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026
mindbodygreen clears it